Faron Pharmaceuticals Oy (“Faron” or “the Company”) Faron Announces New Biomarker Data from Phase I/II BEXMAB Study at EHA2023 Hybrid Congress Bexmarilimab mode of action in AML/MDS supported with durable Clever-1 target engagement in bone marrow, with increases observed in T and NK cells and antigen presentation Clinical activity across indications, with objective responses in 5 … Read more
Data from Phase 3 MORPHO trial selected for press briefing and to be presented as oral session during the 2023 European Hematology Association (EHA) Hybrid Congress Exploratory results demonstrated improvement of relapse-free survival (RFS) in a subgroup of patients with measurable residual disease (MRD) TOKYO and ROCKVILLE, Md., June 9, 2023 /PRNewswire/ — Astellas Pharma … Read more
CHICAGO, June 9, 2023 /PRNewswire/ — The Insect Repellent Active Ingredients Market is estimated at USD 1.0 billion in 2023 and is projected to reach USD 1.5 billion by 2028, at a CAGR of 7.6% from 2023 to 2028 according to a report published by MarketsandMarkets™. The rise in insect-borne diseases, such as malaria, dengue fever, Zika … Read more
CHENGDU, China, June 9, 2023 /PRNewswire/ — On June 8th, 2023, Coviccine® Trivalent XBB.1.5-Recombinant COVID-19 Trivalent (XBB.1.5+BA.5+Delta) Protein Vaccine (Sf9 cell) developed by WestVac Biopharma/ West China Medical Center, Sichuan University was approved for EUA by relevant authorities in China. This is the first COVID-19 vaccine in the world approved for EUA against XBB descendent … Read more
NEW YORK, June 9, 2023 /PRNewswire/ — The pharmaceutical contract research and manufacturing (CRAM) market size is forecast to increase by USD 121.35 billion from 2022 to 2027, at a CAGR of 10.32%, according to the recent market study by Technavio. The growth of the market depends on several factors, including the availability of cost-efficient resources in emerging … Read more
Ministry of Health, Labour and Welfare to evaluate zolbetuximab as treatment option for patients with advanced gastric and gastroesophageal cancers TOKYO, June 9, 2023 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced the submission of a New Drug Application (NDA) on June 9, 2023 to Japan’s Ministry of … Read more
HONG KONG, June 8, 2023 /PRNewswire/ — On 8 June 2023, the 2023 Fosun International Investor Open Day was held in Shanghai. It was the first time that Fosun International had held a large-scale offline open day after the pandemic. More than 100 domestic and foreign investor representatives from BlackRock, J.P. Morgan Securities, UBS SDIC, … Read more
NEW YORK, June 8, 2023 /PRNewswire/ — Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced the pricing of an underwritten public offering of (i) 17,810,000 shares of its … Read more
CHENGDU, China, June 8, 2023 /PRNewswire/ — On June 8th, 2023, Coviccine® Trivalent XBB.1.5-Recombinant COVID-19 Trivalent (XBB.1.5+BA.5+Delta) Protein Vaccine (Sf9 cell) developed by WestVac Biopharma/ West China Medical Center, Sichuan University was approved for EUA by relevant authorities in China. This is the first COVID-19 vaccine in the world approved for EUA against XBB descendent … Read more
DUBLIN, June 8, 2023 /PRNewswire/ — The “Social Anxiety Disorder (SAD) – Market Insight, Epidemiology and Market Forecast – 2032” report has been added to ResearchAndMarkets.com’s offering. The Social Anxiety Disorder (SAD) market report provides current treatment practices, emerging drugs, Social Anxiety Disorder (SAD) market share of the individual therapies, current and forecasted Social Anxiety Disorder (SAD) … Read more